114 related articles for article (PubMed ID: 30215090)
1. Cyclopeptidic photosensitizer prodrugs as proteolytically triggered drug delivery systems of pheophorbide A: part II - co-loading of pheophorbide A and black hole quencher.
Bouilloux J; Yushchenko O; Dereka B; Boso G; Babič A; Zbinden H; Vauthey E; Lange N
Photochem Photobiol Sci; 2018 Nov; 17(11):1739-1748. PubMed ID: 30215090
[TBL] [Abstract][Full Text] [Related]
2. Cyclopeptidic photosensitizer prodrugs as proteolytically triggered drug delivery systems of pheophorbide A: part I - self-quenched prodrugs.
Bouilloux J; Yushchenko O; Dereka B; Boso G; Zbinden H; Vauthey E; Babič A; Lange N
Photochem Photobiol Sci; 2018 Nov; 17(11):1728-1738. PubMed ID: 30215073
[TBL] [Abstract][Full Text] [Related]
3. Double-PEGylated Cyclopeptidic Photosensitizer Prodrug Improves Drug Uptake from In Vitro to Hen's Egg Chorioallantoic Membrane Model.
Bouilloux J; Kiening M; Yapi S; Lange N
Molecules; 2021 Oct; 26(20):. PubMed ID: 34684822
[TBL] [Abstract][Full Text] [Related]
4. Correction: Cyclopeptidic photosensitizer prodrugs as proteolytically triggered drug delivery systems of pheophorbide A: part II - co-loading of pheophorbide A and black hole quencher.
Bouilloux J; Yushchenko O; Dereka B; Boso G; Babič A; Zbinden H; Vauthey E; Lange N
Photochem Photobiol Sci; 2019 Nov; 18(11):2815. PubMed ID: 31642833
[TBL] [Abstract][Full Text] [Related]
5. Enhanced prostate cancer targeting by modified protease sensitive photosensitizer prodrugs.
Zuluaga MF; Gabriel D; Lange N
Mol Pharm; 2012 Jun; 9(6):1570-9. PubMed ID: 22548315
[TBL] [Abstract][Full Text] [Related]
6. Pheophorbide-a conjugates with cancer-targeting moieties for targeted photodynamic cancer therapy.
You H; Yoon HE; Jeong PH; Ko H; Yoon JH; Kim YC
Bioorg Med Chem; 2015 Apr; 23(7):1453-62. PubMed ID: 25753328
[TBL] [Abstract][Full Text] [Related]
7. Tailoring protease-sensitive photodynamic agents to specific disease-associated enzymes.
Gabriel D; Campo MA; Gurny R; Lange N
Bioconjug Chem; 2007; 18(4):1070-7. PubMed ID: 17477499
[TBL] [Abstract][Full Text] [Related]
8. Correction: Cyclopeptidic photosensitizer prodrugs as proteolytically triggered drug delivery systems of pheophorbide A: part I - self-quenched prodrugs.
Bouilloux J; Yushchenko O; Dereka B; Boso G; Zbinden H; Vauthey E; Babič A; Lange N
Photochem Photobiol Sci; 2019 Nov; 18(11):2814. PubMed ID: 31642463
[TBL] [Abstract][Full Text] [Related]
9. Oxime-based 19-nortestosterone-pheophorbide a conjugate: bimodal controlled release concept for PDT.
Pavlíčková V; Jurášek M; Rimpelová S; Záruba K; Sedlák D; Šimková M; Kodr D; Staňková E; Fähnrich J; Rottnerová Z; Bartůněk P; Lapčík O; Drašar P; Ruml T
J Mater Chem B; 2019 Sep; 7(36):5465-5477. PubMed ID: 31414695
[TBL] [Abstract][Full Text] [Related]
10. Photosensitizer conjugated iron oxide nanoparticles for simultaneous in vitro magneto-fluorescent imaging guided photodynamic therapy.
Nafiujjaman M; Revuri V; Nurunnabi M; Cho KJ; Lee YK
Chem Commun (Camb); 2015 Apr; 51(26):5687-90. PubMed ID: 25715169
[TBL] [Abstract][Full Text] [Related]
11. FRET quenching of photosensitizer singlet oxygen generation.
Lovell JF; Chen J; Jarvi MT; Cao WG; Allen AD; Liu Y; Tidwell TT; Wilson BC; Zheng G
J Phys Chem B; 2009 Mar; 113(10):3203-11. PubMed ID: 19708269
[TBL] [Abstract][Full Text] [Related]
12. Protease-triggered photosensitizing beacon based on singlet oxygen quenching and activation.
Chen J; Stefflova K; Niedre MJ; Wilson BC; Chance B; Glickson JD; Zheng G
J Am Chem Soc; 2004 Sep; 126(37):11450-1. PubMed ID: 15366886
[TBL] [Abstract][Full Text] [Related]
13. Novel photosensitizer-protein nanoparticles for photodynamic therapy: photophysical characterization and in vitro investigations.
Chen K; Preuss A; Hackbarth S; Wacker M; Langer K; Röder B
J Photochem Photobiol B; 2009 Jul; 96(1):66-74. PubMed ID: 19442534
[TBL] [Abstract][Full Text] [Related]
14. The chlorophyll catabolite pheophorbide a as a photosensitizer for the photodynamic therapy.
Xodo LE; Rapozzi V; Zacchigna M; Drioli S; Zorzet S
Curr Med Chem; 2012; 19(6):799-807. PubMed ID: 22214455
[TBL] [Abstract][Full Text] [Related]
15. GSH-mediated photoactivity of pheophorbide a-conjugated heparin/gold nanoparticle for photodynamic therapy.
Li L; Nurunnabi ; Nafiujjaman ; Lee YK; Huh KM
J Control Release; 2013 Oct; 171(2):241-50. PubMed ID: 23867285
[TBL] [Abstract][Full Text] [Related]
16. New photodynamic molecular beacons (PMB) as potential cancer-targeted agents in PDT.
Stallivieri A; Colombeau L; Devy J; Etique N; Chaintreuil C; Myrzakhmetov B; Achard M; Baros F; Arnoux P; Vanderesse R; Frochot C
Bioorg Med Chem; 2018 Feb; 26(3):688-702. PubMed ID: 29338907
[TBL] [Abstract][Full Text] [Related]
17. Thrombin-sensitive photodynamic agents: a novel strategy for selective synovectomy in rheumatoid arthritis.
Gabriel D; Busso N; So A; van den Bergh H; Gurny R; Lange N
J Control Release; 2009 Sep; 138(3):225-34. PubMed ID: 19445983
[TBL] [Abstract][Full Text] [Related]
18. Fluorescence characteristics and lifetime images of photosensitizers of talaporfin sodium and sodium pheophorbide a in normal and cancer cells.
Awasthi K; Yamamoto K; Furuya K; Nakabayashi T; Li L; Ohta N
Sensors (Basel); 2015 May; 15(5):11417-30. PubMed ID: 25993516
[TBL] [Abstract][Full Text] [Related]
19. Light-activatable dual-source ROS-responsive prodrug nanoplatform for synergistic chemo-photodynamic therapy.
Yang B; Wang K; Zhang D; Sun B; Ji B; Wei L; Li Z; Wang M; Zhang X; Zhang H; Kan Q; Luo C; Wang Y; He Z; Sun J
Biomater Sci; 2018 Nov; 6(11):2965-2975. PubMed ID: 30255178
[TBL] [Abstract][Full Text] [Related]
20. Polymeric photosensitizer prodrugs for photodynamic therapy.
Campo MA; Gabriel D; Kucera P; Gurny R; Lange N
Photochem Photobiol; 2007; 83(4):958-65. PubMed ID: 17645670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
